Ignite Creation Date:
2024-05-05 @ 11:18 PM
Last Modification Date:
2024-10-26 @ 10:31 AM
Study NCT ID:
NCT01294462
Status:
COMPLETED
Last Update Posted:
2014-06-27
First Post:
2011-02-10
Brief Title:
Study to Assess Safety and Efficacy of Ticagrelor AZD6140 Versus Clopidogrel in AsianJapanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes ACS
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Double-blind Double-dummy Parallel Group International Asian Multicenter Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid ASA Versus Clopidogrel on Top of Low Dose ASA in AsianJapanese Patients With Non-ST or ST Elevation Acute Coronary SyndromesACS for Whom PCI is Planned
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the efficacy prevention of vascular events and safety especially bleedings of Ticagrelor AZD6140 compared with Clopidogrel both given on top of low dose aspirin in AsianJapanese patients with acute coronary syndrome and a planned percutaneous coronary intervention PCI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None